François Salès

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Alexander M.M. Eggermont, Stefan Suciu, Mario Santinami et al. · The Lancet · 2008 · 638 citations

Surgical Oncology, Medicine, Eortc 18991 +7

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

Alexander M.M. Eggermont, Stefan Suciu, Rona M. MacKie et al. · The Lancet · 2005 · 310 citations

Surgical Oncology, Oncology, Melanoma +7

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Alexander M.M. Eggermont, Stefan Suciu, Alessandro Testori et al. · Journal of Clinical Oncology · 2012 · 279 citations · Full text

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

Margarita Salcedo, Nadège Bercovici, Rachel R. Taylor et al. · Cancer Immunology Immunotherapy · 2005 · 137 citations · Full text

Vaccination, Tumor Immunology, Cancer Immunosurveillance +8

On the release and half‐life of S100B protein in the peripheral blood of melanoma patients

Ghanem Ghanem, B. Loir, Renato Morandini et al. · International Journal of Cancer · 2001 · 124 citations · Full text

Immunology, Blood Cell, Pathology +18